Voyager Therapeutics (VYGR) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Wedbush Remains Bullish on Voyager Therapeutics (VYGR) Following 4Q Financials
March 18, 2016 8:29 AM EDTWedbush reiterated an Outperform rating and $36.00 price target on Voyager Therapeutics (NASDAQ: VYGR) following 4Q financial results.
Analyst David Nierengarten commented, "VYGR reported net income of ($8.8M), below our estimate of ($6.1M) in part due to GAAP expenses of $1.5M related to pre-IPO... More
